T.Rx Capital

T.Rx Capital is a Boston-based venture capital firm launched in 2023 by former Pear Therapeutics executives Corey McCann and Michael Langer. The fund focuses on early-stage investments in therapeutics and digital health products by both forming new startups—often with input from scientific adviser Bob Langer—and investing in external pitches. The first fund has a $175 million cap. Notable team members include Liz Kwo (Everly Health), Debbie Lin (Caris Life Sciences), and Kwesi Frimpong-Boateng (Eli Lilly). Their investment approach leverages deep experience at the intersection of technology, biology, business model innovation, and regulatory strategy.